KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Receivables - Net (2016 - 2025)

Pfizer (PFE) has disclosed Receivables - Net for 17 consecutive years, with $11.9 billion as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 3.59% to $11.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 billion through Dec 2025, up 3.59% year-over-year, with the annual reading at $11.9 billion for FY2025, 3.59% up from the prior year.
  • Receivables - Net for Q4 2025 was $11.9 billion at Pfizer, down from $14.3 billion in the prior quarter.
  • The five-year high for Receivables - Net was $16.1 billion in Q4 2022, with the low at $9.9 billion in Q2 2021.
  • Average Receivables - Net over 5 years is $12.1 billion, with a median of $11.7 billion recorded in 2023.
  • The sharpest move saw Receivables - Net surged 45.07% in 2021, then tumbled 32.49% in 2023.
  • Over 5 years, Receivables - Net stood at $11.5 billion in 2021, then fell by 4.59% to $11.0 billion in 2022, then rose by 5.61% to $11.6 billion in 2023, then decreased by 0.89% to $11.5 billion in 2024, then rose by 3.59% to $11.9 billion in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $11.9 billion, $14.3 billion, and $12.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.